Recent Insights on the Medicinal Chemistry of Sickle Cell Disease

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-20T13:24:50Z
dc.date.available2014-05-20T13:24:50Z
dc.date.created2014-05-20T13:24:50Z
dc.date.issued2011-05-01
dc.identifierCurrent Medicinal Chemistry. Sharjah: Bentham Science Publ Ltd, v. 18, n. 15, p. 2339-2358, 2011.
dc.identifier0929-8673
dc.identifierhttp://hdl.handle.net/11449/7810
dc.identifier10.2174/092986711795656117
dc.identifierWOS:000290613300012
dc.identifier9734333607975413
dc.identifier0000-0003-4141-0455
dc.description.abstractSickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. SCD is a genetic disease characterized by punctual mutation that basis on the exchange of glutamic acid to valine in a beta chain of hemoglobin. In deoxygenated state, the interaction among the beta chains leads to hemoglobin polymerization carrying out to deformation of cytoskeleton structure of red blood cells to a sickle shape. Currently, the treatment is performed with the antineoplasic drug hydroxyurea. This review summarizes current knowledge about possible targets and the approaches to discover new compounds to treat the SCD symptoms. Drug design based on therapeutical application and molecular modifications strategies will be discussed.
dc.languageeng
dc.publisherBentham Science Publ Ltd
dc.relationCurrent Medicinal Chemistry
dc.relation3.469
dc.relation1,015
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.subjectChelating agents
dc.subjectdrug discovery
dc.subjecterythrocyte dehydratation
dc.subjectfetal hemoglobin
dc.subjecthydroxyurea
dc.subjectnitric oxide
dc.subjectsickle cell disease
dc.subjectvasodilatation
dc.subjecthemoglobin modifiers
dc.subjecthemoglobin inducers
dc.subjectgardos channel
dc.subjectsickle cell treatment
dc.subjectvasodilation
dc.subjectphytomedicines
dc.titleRecent Insights on the Medicinal Chemistry of Sickle Cell Disease
dc.typeOtros


Este ítem pertenece a la siguiente institución